Linked Life Data

18036042

Source:http://linkedlifedata.com/resource/pubmed/id/18036042

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
12
pubmed:dateCreated
2007-11-26
pubmed:abstractText
Androgen-deprivation therapy for prostate cancer decreases bone mineral density and increases the risk of fracture. The effect of risedronate, a potent third-generation oral bisphosphonate, on bone loss during androgen deprivation therapy was investigated.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
0919-8172
pubmed:author
pubmed:issnType
Print
pubmed:volume
14
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1071-5
pubmed:meshHeading
pubmed:year
2007
pubmed:articleTitle
Preventive effect of risedronate on bone loss in men receiving androgen-deprivation therapy for prostate cancer.
pubmed:affiliation
Department of Urology, Kanto Central Hospital, Tokyo, Japan. ishizaka@kanto-ctr-hsp.com
pubmed:publicationType
Journal Article, Clinical Trial